INTERVENTIONAL CARDIOLOGY

Transcription

INTERVENTIONAL CARDIOLOGY
Slovenia
Japan
Netherlands
Germany
Finland
Sweeden
Netherlands
France
Greece
New Zealand
South Korea
France
Finland
Czech Republic
Netherlands
Finland
Netherlands
United KingdomGermany
Unite States Canada
New Zealand
Sweeden
South Korea
Latvia
Czech
Republic
Japan
Switzerland
Denmark
Slovenia
Canada
United Kingdom
Slovenia
Sweeden
P R O M E D I C A I N T E R N AT I O N A L C M E
Slovenia
Germany
South Korea
France
Denmark
Italy Australia
Switzerland
France
Unite States
Greece
Italy
Finland
Australia
Switzerland
Latvia
Norway
Belgium
Sweeden
South Korea
Czech Republic
Greece
Slovenia
Czech Republic
New Zealand
Germany
Italy
New Zealand
Switzerland
Norway
France
Sweeden
South Korea
Belgium
­INTERVENTIONAL CARDIOLOGY 2015
Latvia
Japan
Norway
Latvia
Australia Japan
Greece
United Kingdom
Slovenia
New Zealand
Switzerland
Belgium
Italy
Denmark
Germany Unite States
Bulgaria
Netherlands
Norway
Unite States
Canada
France
Belgium
Australia
Japan
South Korea
Brazuk
Bulgaria
Poland
Latvia
Bulgaria
Brazuk
Japan United
Netherlands
Italy
Kingdom
Germany
Hungary
Netherlands
Japan Croatia
Latvia
Denmark
Bulgaria
Italy
Spain
Finland
United
Kingdom Italy
Norway
Slovenia
New Zealand
New Zealand
Switzerland
Netherlands
Finland
Hungary
Norway Bulgaria
Belgium
Poland
SpainCanada Latvia
United Kingdom
Romania
UniteLatvia
States
Canada
Belgium
Bulgaria
Japan
Spain
Czech Republic
Greece
Czech
Republic
Russia
Poland
Unite States
Australia Brazuk
Norway
Spain
Slovenia Bulgaria
Poland
Greece
Croatia
Australia
Greece
Canada Poland
Czech Republic
Croatia
Slovenia
Hungary
Poland
Finland
Republic of
Macedonia
Russia
Netherlands
Poland
Hungary
Finland
Brazuk
Unite States
Norway
Republic of
Russia
Macedonia
New Zealand
Germany
Switzerland
Australia
Czech Republic Japan
Unite States Latvia United Kingdom
Denmark
Greece
Italy Czech Republic
Denmark
Brazuk
Poland Finland
Italy
Japan
Norway
Croatia
Romania
Poland
Austria
Belgium
Latvia
Denmark
Brazuk
Canada
United Kingdom
Netherlands
Latvia
Greece
Italy
Brazuk
Poland
Austria
Bulgaria
Republic of
Macedonia
Poland
Croatia
Finland
Netherlands
Slovenia Latvia
Norway
Greece
Netherlands
Spain
Slovenia
Latvia
Finland
Bulgaria
Latvia
NorwayCzech Republic
Poland
Bulgaria
Republic of
Macedonia
Austria
Hungary
Romania
Brazuk
Russia
Russia
Belgium
Canada
Greece
Brazuk
FinlandSlovenia
Romania
Republic of
Macedonia
Austria
Bulgaria
Croatia
Latvia
Hungary
Bulgaria
Romania
Norway
Belgium
Brazuk
Croatia
Bulgaria
Poland
SpainBelgium
Norway
Austria
Norway
Belgium
Republic of
Macedonia
Russia
Czech Republic
Norway
Belgium
Poland
Austria
Brazuk
Spain
Russia
Spain
Romania
Spain
Brazuk
Croatia
Republic of
Macedonia
Austria
Croatia
Romania
Brazuk
Poland
Spain
Republic of
Macedonia
Hungary
Romania
Brazuk
Poland
Hungary
Poland
Austria
Russia
Czech
Republic
Finland
Spain
Belgium
Czech Republic
Finland
Latvia
Croatia
Spain
Russia
Canada
Norway
United
Kingdom
Slovenia
Romania
Netherlands
Romania
Republic of
Macedonia
Hungary
Hungary
CzechAustralia
Republic
United Kingdom
Croatia
Bulgaria
Republic of
Macedonia
Slovenia
Unite
States
New Zealand
Australia
Unite States
Denmark
Canada
United Kingdom
Greece
ItalyNetherlands
Czech Republic
Finland
BulgariaItaly
Greece
Slovenia
Poland
Spain Norway
Netherlands
Belgium
Spain
Brazuk
Russia
Australia
New Zealand
Greece
Switzerland
Romania
Bulgaria
Belgium
Hungary
Canada
Switzerland
Sweeden
Spain
Austria
Hungary
Bulgaria
New Zealand
Denmark Switzerland
United Kingdom
Germany
Sweeden
South Korea
France
South Korea
Germany Australia
Slovenia
France
Bulgaria Netherlands
Romania
Czech Republic
Croatia
South Korea
Japan
Australia
Unite
States
Finland
New
Zealand
DenmarkSwitzerland
Canada
United
Kingdom
Japan
SweedenNetherlands
FranceSlovenia RomaniaGermany South Korea
Unite
States
Norway Greece
BelgiumSlovenia
Italy
Denmark
Austria
Russia
Brazuk
Spain
Latvia
Australia
Unite States
Sweeden
South Korea
Japan
Unite States
Italy Switzerland
Czech Republic
FinlandUnited Kingdom Germany
Japan
Canada
Germany Sweeden
France
South Korea
Canada
Italy
Bulgaria
Japan
New Zealand
Canada
France
Romania
Belgium
Spain
Belgium
Austria
Hungary
New Zealand
Austria
United Kingdom
Netherlands
Denmark
Czech Republic
Austria
Russia
Austria
Russia
Norway
Croatia
Greece
Republic of
Macedonia
Netherlands
Switzerland
Sweeden
Comprehensive Approach to the Percutaneous
Management of Structural Heart Disease and
Coronary and Peripheral Vascular Disease
Spain
UnitedBulgaria
Kingdom
Finland
Hungary
Latvia
Brazuk
Japan
Croatia
Spain
Latvia
Netherlands
Italy
Slovenia
Greece Latvia
Italy
Brazuk
Hungary
Romania
Russia
Republic of
Croatia
Norway
Belgium
Macedonia
Hungary
Republic of
Macedonia
Italy
Germany
Australia
Spain
Republic of
Croatia
Austria
Republic
of
Macedonia
Macedonia
Denmark
Czech RepublicNorway
Belgium
Greece
Sweeden
Slovenia
Finland
Australia Netherlands Brazuk
Poland
Republic of
Croatia
Macedonia
Latvia
Finland
Italy
South
Korea Unite
Bulgaria
States
Austria
Republic of
Macedonia
Denmark
Unite States
South Korea
Brazuk
France
Sweeden
Latvia
DenmarkGreece Netherlands
Switzerland
Russia
Japan
Sweeden
Norway
Belgium
Brazuk
New Zealand
Switzerland
Canada
Germany
Switzerland
Denmark
United Kingdom
Bulgaria
Poland
Germany
Australia
Czech
Republic Slovenia
Greece
Denmark
United Kingdom
Finland
UniteCanada
States
South Korea
Spain
Italy
Germany
Republic France
of
Macedonia
France
Poland
30TH ANNUAL INTERNATIONAL SYMPOSIUM
Denmark Poland
France
Czech Republic
Finland
Republic of
Croatia
Macedonia
Croatia
Austria
Hungary
Russia
Romania
Austria
Russia
Spain
Republic of
Macedonia
Republic of
Macedonia
Croatia
Republic of
Macedonia
Croatia
Hungary
Hungary
Russia
Croatia
Hungary
Hungary Austria
Russia
Russia
Romania
Austria
Austria
Russia
Romania
Romania
Hungary
Russia
Romania
COURSE DIRECTOR
James R. Margolis, MD, FACC
Endorsed by the California and Colorado Chapters
of the American College of Cardiology
The Westin Snowmass Resort, Snowmass Village, Colorado
March 1-6, 2015
Romania
INTERVENTIONAL CARDIOLOGY 2015: 30 TH ANNUAL INTERNATIONAL SYMPOSIUM
In January 1984, by serendipity, Andreas Grüntzig and I found ourselves alone in Snowmass for
different business reasons. We took the occasion to ski together for two long and wonderful days.
On the ski lifts, we talked about many things, but mostly angioplasty, as PCI was called in those
days. It was from these discussions that an interventional cardiology meeting in Snowmass was born.
From the outset, the purposes of this meeting were:
> To explore ways to improve the still young technique, and to expand its reach.
> To partner with industry in these endeavors.
>To foster international cooperation and exchange of ideas, an extension of the teaching
principles that Grüntzig had initiated seven years earlier.
>To do all of this in a pleasant environment that encouraged camaraderie as opposed
to competition.
The first few meetings were quite small, consisting of didactic presentations and showing of edited
videotapes from our live demonstration courses in Miami. But these early meetings adhered closely to
our core objectives. It became clear that Snowmass was an excellent venue for the exchange of ideas
not only in the lecture hall, but also in social venues and on ski lifts. As the meeting grew in size and
stature, the European participation grew proportionately. This is how it was for 15 years.
In 2000, on the advice of Patrick Serruys, we switched to the international format that persists today.
It was at this time that we added participation from Japan and Korea. The international format
provided an opportunity to better focus on our core values, and to keep the course fresh with a
healthy turnover of young, previously undiscovered faculty and exposure to ideas and methodologies
from far off lands. The new format exposed attendees to cutting edge work performed both in and
outside the U.S. More importantly, with faculty from more than 25 countries on five continents the
audience gained a perspective of how differing socioeconomic factors alter the performance of PCI in
different cultures and different countries – usually achieving comparable results.
Finally, the international format fosters, albeit in a small way, behavior conducive to world peace. In
these turbulent times, academic and scientific exchanges may be useful in counteracting the rhetoric
and irresponsible actions of world leaders.
This year we will continue to passionately adhere to our mission while presenting an exciting didactic
program combined with a celebration of thirty wonderful years in Snowmass. We will look back to
see where we have been while exploring where we are going. As course director, I have had the honor
and great pleasure of interacting with so many brilliant and fascinating individuals that this interaction
by itself would have made it all worthwhile. During the meeting, I will introduce you to these people
and recognize their contributions. Please join us for a fascinating ride from the past to the future and
all that in between.
James R. Margolis, MD, FACC
Course Director
C A L L F O R A B S T R A C T S : S U B M I S S I O N D U E D A T E J A N U A R Y 1 6 , 2 01 5
Submissions of original abstracts are being accepted for oral presentation and electronic poster display.
To submit your abstracts, please visit www.promedicacme.com.
K E Y T H E M E S F O R 2 01 5
Without a doubt, TAVR is the most exciting advance in interventional cardiology in recent years.
Not only does the procedure work, it has been proven conclusively that it saves lives. Newer valves
and newer iterations of older valves have made the procedure easier, safer and available to a rapidly
expanding patient population. This year, we have devoted a major portion of our program to TAVR
with more than 30 talks from operators with a combined experience of thousands of cases. These
talks cover global experience, patient selection, techniques, avoidance and treatment of complications
and discussion of various valves both on the market and those in clinical evaluation. Included is a
seven talk mini-symposium on the Achilles heel of TAVR, neurological complications. The symposium
concludes with a discussion of modalities for TVT of the mitral valve.
A minor but important theme of the 2015 meeting is devoted to discussion of the meaning of
one or more negative studies of treatment modalities that physicians believe are effective, despite
a lack of 1A evidence. Talks in this genre start out with the title: “Is the Data Right and the Doctor
Wrong, or Vice Versa?”
LEARNING OBJECTIVES
Upon completion of this symposium, participants should be able to:
> Better understand the meaning of negative studies.
> Gain a comprehensive picture of TAVR.
> Integrate advances in electrophysiology into their practice.
> Better manage complications of coronary and peripheral percutaneous interventions.
> Discuss the controversies surrounding the indication for coronary stents, efficacy, and complications.
>G
ain an international perspective of percutaneous interventions including the effect of a country’s
economics on how interventions are performed.
C M E AC C R E D I TAT I O N A N D D E S I G N AT I O N
Promedica International CME is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education
for physicians.
Promedica International CME designates this live activity for a maximum of 30.5 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation
in the activity.
Provider approved by the California Board of Registered Nursing, Provider #8495 for 30.5
contact hours.
The American Board of Cardiovascular Perfusion (ABCP) has approved this symposium for a maximum
of 27.2 Category 1 CEUs for Sunday, March 1 (5.4 CEUs), Monday, March 2 (5.0 CEUs), Tuesday,
March 3 (5.4 CEUs), Wednesday, March 4 (4.8 CEUs), Thursday, March 5 (4.6 CEUs), and Friday,
March 6 (2.0 CEUs).
E U R O P E A N AC C R E D I TAT I O N
Due to a mutual recognition between the AMA and the UEMS, European participants may convert
AMA Category 1 Credits.
AC T I V I T Y E VA L UAT I O N
Evaluation by online questionnaire will address content, presentation and future educational needs.
COMMERCIAL SUPPORT
This program is supported, in part, by educational grants and exhibits from industry, in accordance
with the ACCME Standards for Commercial Support. At the time of printing, a complete list of
commercial supporters was not available. Appropriate acknowledgement will be given to all supporters
in meeting materials onsite.
COURSE DIRECTORS AND FACULTY
COURSE DIRECTOR
James R. Margolis, MD, FACC
USA
C OURSE
CO-DIRECTORS
Dariusz Dudek, MD, PhD
Poland
Osamu Katoh, MD
Japan
Jacques J. Koolen, MD, PhD
The Netherlands
Martin B. Leon, MD, FACC
USA
M. Pauliina Margolis, MD, PhD
USA/Finland
Seung-Jung Park, MD, PhD, FACC
South Korea
Augusto D. Pichard, MD, FACC
USA
Nicolaus Reifart, MD, FACC
Germany
SCIENTIFIC
COMMITTEE
Jorge Belardi, MD, FACC
Argentina
Patrick Kay, MD, PhD
New Zealand
Hideo Nishikawa, MD, PhD
Japan
Marko Noc, MD, PhD
Slovenia
Michael Pieper, MD
Switzerland
Kari I. Saunamäki, MD, PhD
Denmark
Robert S. Schwartz, MD
USA
Gerald S. Werner, MD, PhD, FACC
Germany
FACULTY
Kevin Abrams, MD
USA
Takashi Akasaka, MD
Japan
Yolande Appelman, MD, PhD
The Netherlands
Stanislaw Bartus, MD, PhD
Poland
Andreas Baumbach, MD
United Kingdom
Diego F. Belardi, MD
Argentina
Brian T. Bethea, MD
USA
Guus Brueren, MD, PhD
The Netherlands
Leszek Bryniarski, MD, PhD
Poland
Matjaz Bunc, MD, PhD
Slovenia
Mark W. Burket, MD, FACC
USA
Pawel E. Buszman, MD, PhD, FACC
Poland
Piotr P. Buszman, MD, PhD
Poland
David Clark, MBBS
Australia
Peter Clemmensen, MD, DMSc
Denmark
Justin Davies, MD, PhD
United Kingdom
Pieter den Heijer, MD, PhD
The Netherlands
Willem Dewilde, MD
The Netherlands
Pieter A. Doevendans, MD, PhD
The Netherlands
Thomas Engstrøm, MD, PhD, DMSci
Denmark
Andrjes Erglis, MD, PhD, FACC
Latvia
Witold Gerber, MD, PhD
Germany
Robert J. Gil, MD, PhD
Poland
Luis Guzmán, MD, FACC
USA
Michal Hawranek, MD, PhD
Poland
Timothy D. Henry, MD, FACC
USA
Richard R. Heuser, MD, FACC
USA
Gerhard Hindricks, MD, PhD
Germany
Ota Hlinomaz, MD, PhD
Czech Republic
Kurt Huber, MD, FACC
Austria
Nikolaj Ihlemann, MD, PhD
Denmark
Charles Ilsley, MD
United Kingdom
David Gareth Jones,
BSc(Hons), MBBS, MD(Res)
United Kingdom
Petr Kala, MD, PhD
Czech Republic
Zbigniew Kalarus, MD, PhD
Poland
David Kallend, MBBS
USA
Anne Kaltoft, MD, PhD
Denmark
Samir Kapadia, MD, FACC
USA
Dimitri Karmpaliotis, MD, PhD, FACC
USA
Sasko Kedev, MD, PhD, FACC
Republic of Macedonia
Hyo-Soo Kim, MD, PhD
South Korea
Young-Hak Kim, MD, PhD
South Korea
Karel T. Koch, MD, PhD
The Netherlands
Bon-Kwon Koo, MD, PhD, FACC
South Korea
Hans Krankenberg, MD
Germany
Alexandra Lansky, MD, FACC
USA
Jens Flensted Lassen, MD, PhD
Denmark
Seung-Whan Lee, MD, PhD
South Korea
Jacek Legutko, MD, PhD
Poland
Maciej Lesiak, MD, PhD
Poland
Michael J. Mack, MD, FACC
USA
Hooman Madyoon, MD, FACC
USA
Raj Makkar, MD, FACC
USA
Kambis Mashayekhi, MD
Germany
Mark Mason, MD
United Kingdom
Evgeny Merkulov, MD, PhD
Russia
Markus Meyer-Gessner, MD
Germany
Krzysztof Milewski, MD, PhD
Poland
Vsevolod Mironov, MD
Russia
Jeffrey W. Moses, MD, FACC
USA
Blaz Mrevlje, MD
Germany
Christoph A. Nienaber, MD, PhD
Germany
Andrzej Ochala, MD
Poland
Lisette Okkels Jensen, MD, DMSci
Denmark
Aleksander G. Osiev, MD, PhD
Russia
Duk-Woo Park, MD, PhD
South Korea
Radoslaw Parma, MD, PhD
Poland
Hrvoje Pintarić, MD, PhD
Croatia
Christopher Piorkowski, MD
Germany
Mark Pitney, MBBS
Australia
Aleksey Protopopov, MD
Russia
Ðeiti Prvulović, MD
Croatia
Maria Radu, MD, PhD
Denmark
Tomasz Rakowski, MD, PhD
Poland
Hanne Berg Ravn, MD, PhD
Denmark
Michael J. Rinaldi, MD, FACC
USA
Jamil A. Saad, MD, FACC
Brazil
Katherine Shreyder, MD, PhD
Russia
Andre R. Simon, MD, PhD
United Kingdom
Pieter Smits, MD, PhD
The Netherlands
Grzegorz Smolka, MD, PhD
Poland
Helle Søholm, MD, PhD
Denmark
Philipp Sommer, MD
Germany
Dace Sondore, MD
Latvia
Jong-Min Song, MD, PhD
South Korea
Hans Störger, MD
Germany
Karlis Strenge, MD
Latvia
Gunnar Tepe, MD
Germany
Pim A.L. Tonino, MD, PhD
The Netherlands
Etsuo Tsuchikane, MD, PhD
Japan
Kazushi Urasawa, MD, PhD
Japan
BJL Van den Branden, MD, PhD
The Netherlands
Jan Van der Heyden, MD, PhD
The Netherlands
Hans-Friedrich Voehringer, MD
Germany
Robert A. Vogel, MD, FACC
USA
Szilard Voros, MD, FACC
USA
Kristian Wachtell, MD, PhD, FACC
Denmark
Darren L. Walters, MBBS, MPhil
Australia
Timothy Watson, MD
New Zealand
Steven K. White, BSc, MBChB
United Kingdom
Andrew Wilson, MBBS, PhD
Australia
Adam Witkowski, MD, PhD
Poland
Wojciech Wojakowski, MD, PhD
Poland
Lucian Zarma, MD
Romania
S C I E N T I F I C P R O G RBulgaria
A M 2 0 15
Brazuk
Spain
S U N D AY, M A R C H 1
7:00 – 10:00 AM
Republic of
Macedonia
MORNING SESSION
Croatia
Austria
RUSSIAN SESSION
Sweeden
ea
d
Poland
AUSTRALIA/
NEW
SESSION
Zealand ZEALAND
Sweeden
SouthNew
Korea
Hungary
Chairman:
Patrick Kay, MD, PhD
s
Switzerland
Australia
dom
Unite States
Canada
New Zealand
Australia
Controversies
in the Use of FFR
Andrew Wilson, MBBS, PhD
Treating Shock
in the Elderly
Canada
David Clark, MBBS
United Kingdom
Slovenia
Radiation in the Cathlab:
Slovenia
Angles, Projections,
Positions
– Do They Really Matter?
Mark Pitney, MBBS
Greece
Czech Republic
Finland
Belgium
Czech Republic
Necessity is the Mother
of Invention
Timothy Watson,
MD
Norway
Belgium
Brazuk
Hypertension: Is There
Still Room for a NonBrazuk
Poland
pharmacological
Approach?
Patrick Kay, MD, PhD
Initial Experience
with the Lotus Transcatheter
Aortic Valve Implantation
System: What Do Newer
Croatia
Austria
Generation
Devices Bring
Romania
to
the TAVI Table?
Darren L. Walters, MBBS, MPhil
Spain
Austria
Russia
Romania
3:30 – 6:00 PM
France
AFTERNOON SESSION
South Korea
Sweeden
Chairman:
Evgeny Merkulov, MD, PhD
AMERICAN SESSION I:
TAVR SESSION, PART I
Current Situation with LAA
Closure Procedures in Russia:
Experience with Complex
LAA Closure Cases
Evgeny Merkulov, MD, PhD
Chairmen:
Michael J. Mack, MD, FACC, and
Augusto D. Pichard, MD, FACC
Russia
Romania
Germany
Japan
Denmark
Grace-score Predicts Short
and Long-term Mortality but
Overestimates the Mortality
Risk in ACS Patients Treated
with PCI of LM Stenosis
Katherine Shreyder, MD, PhD
Italy
Netherlands
Fractional Flow Reserve
Measurement for Decision
Making in Multivessel
Flow and Diffuse Coronary
Artery Disease
Vsevolod Mironov, MD
Latvia
Bulgaria
Hybrid and Pure Endovascular
Approaches in Patients
with Aortic Dissections
and Aneurysms
Aleksey Protopopov, MD, PhD
Republic of
Macedonia
How to Improve Support
during CTO PCI
Aleksander G. Osiev, MD, PhD
Hungary
Retrograde CTO PCI in the US:
A Magnificent Journey
Dimitri Karmpaliotis, MD, PhD, FACC
Venous Disease, the Missing
Link…An Update
Hooman Madyoon, MD, FACC
Switzerland
Unite States
United Kingdom
New Zealand
Australia
Canada
Global Results of TAVR
Martin B. Leon, MD, FACC
Greece
Slovenia
Finland
Czech Republic
Current Status of TAVR
in US and Future Prospects;
Update on the PARTNER
Trials; US TVT Registry
Michael J. Mack, MD, FACC
Outcomes on Inoperable
Patients
Raj Makkar, MD, FACC
Norway
Poland
Belgium
Brazuk
CoreValve: Pros and Cons
Augusto D. Pichard, MD, FACC
Spain
Patient Selection for TAVR
Augusto D. Pichard, MD, FACC
Alternative Access for TAVR
Michael J. Mack, MD, FACC
Croatia
Austria
Preventing Vascular
Complications
Samir Kapadia, MD
Russia
Romania
Conscious Sedation for TAVR
Augusto D. Pichard, MD, FACC
AV Block and PPM after TAVR
Raj Makkar, MD, FACC
TAVR for Pure AR
Augusto D. Pichard, MD, FACC
AR Complicating TAVR:
How to Prevent
and How to Treat
Samir Kapadia, MD
Transcatheter Mitral Valve
Innovations, Part I
Brian T. Bethea, MD
In celebration of our 30th anniversary, each day we will look back over
the past 30 years including video of live cases from the 90’s, slide presentations
from past meetings, and a little bit of nostalgia.
S C I E N T I F I C P R O G R A M 2 015
Greece
Italy
Netherlands
M O N D AY,
M A R C H 2 Finland
Latvia
7:00 – 10:00
AM
Norway
MORNING SESSION
South Korea
Switzerland
Bulgaria
New Zealand
Poland
Unite States
Australia
Spain
New Aortic Valve Devices
Michael J. Mack, MD, FACC
Canada
Republic of
Macedonia
MINI-SYMPOSIUM
ON NEUROPROTECTION
Greece
Stroke in TAVR:
Is it a Deal Breaker?
Samir Kapadia, MD
Croatia
Slovenia
Hungary
Finland
Czech Republic
France
South Korea
SOLACI SESSION
Switzerland
Brazuk
Unite States
Belgium
Germany
Sweeden
AMERICAN SESSION II
United Kingdom
Slovenia
Russia
STEMI in Latin America:
Challenges to Match
Established Standards of Care
Chairman:
Jorge Belardi, MD, FACC
Japan
Denmark
United Kingdom
Finland
Czech Republic
Norway
Wearable Cardiac
Defibrillators as a Bridge
to ICD Post STEMI: What
is the Evidence behind It?
Diego F. Belardi, MD
Brazuk
Impact of MRI Methodology
on DWI MRI Lesion
Volume Measurements
and Statistical Implications
Szilard Voros, MD, FACC
Spain
Croatia
Austria
Neuroprotection:
Importance of Covering
All Three Cerebral Vessels;
Lessons from DEFLECT 1 and 2
Andreas Baumbach, MD
Russia
Romania
Cerebral Protection Devices:
Deflection vs. Capture;
Pros and Cons
Jeffrey W. Moses, MD, FACC
Update on Keystone Heart
Clinical Program and Results
Alexandra Lansky, MD, FACC
France
MR and TAVR
Augusto D. Pichard, MD, FACC
Germany
Valve in Valve for
Degenerated Bioprosthetic
Aortic and Mitral Valves
Samir Kapadia, MD
Japan
Denmark
Transcatheter Mitral
Innovations, Part II
Michael J. Mack, MD, FACC
Italy
Netherlands
Latvia
Bulgaria
Bulgaria
Poland
France
Spain
Germany
Japan
3:30 – 6:00Denmark
PM
AFTERNOON SESSION
Hungary
Russia
ORAL ABSTRACT SESSION I
New Technology for DEBs
Piotr P. Buszman, MD, PhD, FACC
Italy
Greece
Netherlands
Finland
A Controlled Local Drug
Delivery for Plaque Treatment
with Polymer Microspheres
Krzysztof Milewski, MD, PhD
Latvia
Norway
KOREAN SESSION
Bulgaria
Poland
Chairman:
Seung-Jung Park, MD, PhD, FACC
South Korea
Sweeden
Spain
Optimal Stenting Strategy for
Bifurcation Coronary Lesions:
Lessons from the CROSS and
PERFECT Trials
Young-Hak Kim, MD, PhD
Switzerland
New Zealand
Republic of
Macedonia
Unite States
Croatia
Australia
Hungary
Canada
Russia
Changing Paradigm in
Bifurcation Intervention
Using the Contemporary DES:
Lessons from the Korean
Bifurcation Registry
Hyo-Soo Kim, MD, PhD
United Kingdom
Greece
Slovenia
Finland
Czech Republic
Temporal Changes of PCI vs.
CABG for Left Main Disease
Seung-Jung Park, MD, PhD, FACC
Norway
Poland
Spain
Belgium
Brazuk
United Kingdom
United Kingdom
New Zealand
New Zea
Australia Australia
Canada
Canada
Greece
Greece
Slovenia Slovenia
Finland
Finland
Czech Republic
Czech Re
3D Echocardiography-guided
Percutaneous Transcatheter
Closure of Atrial Septal Defect
Jong-Min Song, MD, PhD
Latvia
Latvia
New Zealand
Switzerland
United Kingdom
Unite States
Unite States
Sweeden Sweeden
Sweeden
South Korea
Croatia
Italy
Netherlands
Netherlands
Brazuk
Switzerland
Switzerland
CT-derived Hemodynamic
Assessment: Current and
Future Applications
Bon-Kwon Koo, MD, PhD, FACC
Italy
Belgium
Austria
Norway Norway
Current TAVI: SAPIEN XT
vs. Core Valve
Seung-Jung Park, MD, PhD, FACC
Australia
Unite States
Republic of
Macedonia
Japan
Denmark Denmark
Romania
South Korea
South Korea
Optimal Duration of Dual
Antiplatelet Therapy
after Drug-Eluting Stent
Implantation for Off-Label
vs. On-Label Indication
Duk-Woo Park, MD, PhD
Netherlands
The New Paradigm in
the Treatment of Acute MI
Luis A. Guzmán, MD, FACC
France
Germany Germany
Canada
Slovenia
DWI MRI Lesions as Surrogates
of Cognitive Dysfunction
Kevin Abrams, MD
Poland
France
Greece
STEMI in Brazil:
National Registries
Jamil A. Saad, MD, FACC
Belgium
Australia
Italy
Austria
Carotid Artery
Compression Theory
Robert S. Schwartz, MD, FACC
Norway
Atherosclerotic Burden
and its Clinical Impact of
Asymptomatic Diabetes
According to Risk
Stratification
Seung-Whan Lee, MD, PhD
New Zealand
Japan
STEMI: Stent for Life Program
in Argentina
Jorge Belardi, MD, FACC
Latvia
Czech Republic
Sweeden
Bulgaria Bulgaria
BALKAN SESSION
Canada
Poland
Poland
Spain
Spain
Belgium Belgium
Brazuk
Brazuk
Austria
Austria
Romania
Chairmen:
Marko Noc, MD, PhD, and
Sasko Kedev, MD, PhD, FACC
Slovenia
Republic ofRepublic of
MacedoniaMacedonia
Croatia
Croatia
Czech Republic
Stroke Prevention in the
Hands of Interventional
Cardiologists?
Marko Noc, MD, PhD
Hungary Hungary
Russia
Russia
Belgium
Wrist Access (Radial and
Ulnar) as a Primary Approach
for Carotid Artery Stenting
Sasko Kedev, MD, PhD, FACC
Brazuk
TAVR in the Balkans
Matjaz Bunc, MD, PhD
Austria
STEMI Cooling after CHILL
MI: Case Closed?
Marko Noc, MD, PhD
Romania
Differences in sVCAM-1 in
Patients Undergoing Stenting
and Paclitaxel-coated Balloon
Ðeiti Prvulović, MD
Cardiogonimetry:
Do we need Another
Non-invasive Diagnostic
Method for Suspected
CAD in Women Prior
to Coronary Angiography?
Hrvoje Pintarić, MD, PhD
Romania Roman
France
Germany
New Zealand
Sweeden
Switzerland
South Korea
France
Japan
Germany
Unite States
Switzerland
Japan
Australia
Unite States
Canada
United Kingdom
France
T U E S D AY, M A R C H 3
Denmark
7:00
– 10:00
AM
Canada
United
Kingdom
Germany
Monday
Evening
Session
Greece
Slovenia
DenmarkItaly
Lagniappe SESSION
MORNING
Italy
South Korea
–
Greece Finland
Japan
Switzerland
New Zealand
Japan
Unite States
Australia
Sweeden
Follow-up Results of the
Percutaneous Septal Sinus
Shortening (the MVRx
System) for the Treatment
of Functional Mitral
Regurgitation
Andrejs Erglis, MD, PhD, FACC
Switzerland
Unite States
Slovenia Czech Republic
Latvia
Bulgaria
Finland Norway
Australia
Norway Poland
Italy
BelgiumBrazuk
Optimal Uptake Area
for the STEMI Network:
Time for a Change?
Perspectives from a
Single MEGA Center
Peter Clemmensen, MD, DMSc
Poland Spain
France
Netherlands
Brazuk
Croatia
United Kingdom
Netherlands
Greece
Latvia
Hungary
Russia
Norway
Russia
Japan
FranceRomania
Republic of
Macedonia
Denmark
Japan
HungaryItaly
Implications of Left
Ventricular Hypertrophy
in STEMI Patients Treated
Denmark
with Primary PCI
Thomas Engstrøm, MD, DMSci, PhD
Netherlands
Latvia
Italy
Primary PCI in Patients
with STEMI and Pre-hospital
Cardiac Arrest – Netherlands
Why Some People Arrest
and Others Do Not
Helle Søholm, MD Latvia
Bulgaria
Cause and Time of Death
Associations in Patients
Bulgaria
Treated with Percutaneous
Coronary Intervention
for Non ST-Elevation
Myocardial Infarction
Kristian Wachtell, MD, PhD
Republic of
Macedonia
Hungary
Novel Technique for Distal
of
LMCA Lesions UsingRepublic
DES
and
Macedonia
ABSORB: One-year Follow-up
Dace Sondore, MD
Hungary
Coronary OCT – Quo
Vadis?
Maria Radu, MD, PhD
The Nordic Dedicated
Bifurcation Stent Study –
Rationale and Design
Jens Flensted Lassen, MD, PhD
United Kingdom
Poland
Greece
New Zealand
Switzerland
Spain
Republic of
Macedonia
Latvia
Very Late Sweeden
Stent Thrombosis:
Updates from the SORT OUT
Program
New Zealand
Switzerland
Lisette Okkels Jensen, MD, DMSci
Hungary
Bulgaria
Austria
United Kingdom
Belgium
Canada
Brazuk
Slovenia
Finland
Croatia
Norway
Czech Republic
Austria
Belgium
Australia
Unite States
South Korea
Croatia
Australia
CENTRAL/EASTERN
EUROPEAN SESSION II
Coronary Revascularization
in Stable Angina
Netherlands
Brazuk
Right Ventricular Failure and
Mechanical Support
Hanne Berg Ravn, MD, PhD
Czech Republic
Spain
Sweeden
South Korea
Poland
New Zealand
Stem Cells in CV Disease –
We Need Second Generation
Cell Products!
Wojciech Wojakowski, MD, PhD
Belgium
Renal Denervation after HTN3
Anne Kaltoft, MD, PhD
Romania
How to Improve the
Present Good Outcome
of STEMI? LookingGermany
for
High-risk Subgroups
Kari I. Saunamäki, MD, PhD
Norway
Italy
Austria
Germany
Unite States
Czech Republic
Bulgaria
Sweeden
Slovenia
ACS in Patients Less Than
45 Years Old
Robert J. Gil, MD, PhD
Slovenia
Finland
Primary PCI in Latvia:
Lessons from Registry of Latvia
Acute Coronary Syndrome
Karlis Strenge, MD, PhD
Croatia
Finland
Japan
France
Republic of
Macedonia
Hungary
Switzerland
Canada
Transcatheter Mitral Valve
Implantation: Experience from
the First In-human Cases
Nikolaj Ihlemann, MD, PhD,
Lars Søndergaard, MD, DMSc,
Susanne Holme, MD,
and Peter Bo Hansen, MD
Austria
Bulgaria
South Korea
Canada
Bioresorbable Scaffolds for
PCI in ACS – In-hospital and
Long-term Outcomes
Dariusz Dudek, MD, PhD
Greece
Denmark
Latvia
Spain
Republic of
Macedonia
United Kingdom
Germany
Czech Republic
Denmark
Belgium
Chairmen:
Andrejs Erglis, MD, PhD, FACC,
M. Pauliina Margolis, MD, PhD,
and Kari I. Saunamäki, MD, PhD
Bulgaria
Change in the Landscape of
Antiplatelet Treatment in ACS
Tomasz Rakowski, MD, PhD
New Zealand
Italy
Latvia
Netherlands
Sweeden
Germany
Denmark
SCANDINAVIAN SESSION
Netherlands
South Korea
Australia
New Zealand
Canada
Russia
Brazuk
Romania
Chairmen:
Dariusz Dudek, MD, PhD,
Jacek Legutko, MD, PhD,
and Lucian Zarma, MD
Poland
Spain
– 6:00Australia
PM
Unite3:30
States
Greece
Slovenia
Romania
Russia
AFTERNOON SESSION
Republic of
Macedonia
CENTRAL/EASTERN
Canada
EUROPEAN SESSION I
Urgent and Elective Coronary
Revascularization
Greece
Slovenia
United Finland
Kingdom
Norway
Czech Republic
Belgium
Hungary
Brazuk
Chairmen:Czech Republic
Dariusz Dudek, MD, PhD,
Petr Kala, MD, PhD,
Norway
Belgium
and Jacek Legutko, MD, PhD
Finland
Poland
Spain
Acute Coronary Syndromes
Brazuk
in 2015: Update
on Logistics,
Treatment, and First vs.
Second Generation DES
Spain
in High-risk ACS Patients:
Katowice-Zabrze Registry
of 2000 patients
Wojciech Wojakowski,
MD, PhD
Croatia
Austria
Poland
Croatia
Russia
Russia
Austria
Romania
Stent for Life Initiative
Achievements in STEMI
Patients in Europe and Beyond
Romania
Petr Kala, MD, PhD
Stent for Life Initiative in
Poland – Update on Logistics
and Clinical Outcomes in
STEMI and NSTE ACS
Jacek Legutko, MD, PhD
IVUS-guided Bifurcation
Stenting – New Insights from
the BLAST and Other Studies
Jacek Legutko, MD, PhD
Croatia
Austria
Safety and Efficacy of the
New Generation Bifurcation
Dedicated Stent BiOSS LIM –
Final Results of the POLBOS
II Study
Robert J. Gil, MD, PhD
Russia
Romania
Breaking the Limits or Just
Breaking the Struts? One-year
Clinical and Angiographic
Outcomes after Implantation
of Bioresorbable Scaffolds in
Coronary Bifurcation Lesions
Maciej Lesiak, MD, PhD
First In-man Experience with New Microcatheter
NovaCross™ in Chronic
Total Occlusions
Leszek Bryniarski, MD, PhD
France
South Korea
Sweeden
S C I E N T I F I C P R O G R A M 2 0 15
Germany
TU E S DAY c ont inu ed
One-year Clinical and
Angiographic Outcomes
after Implantation of
Bioresorbable Scaffolds
in Chronic Total Occlusions
Maciej Lesiak, MD, PhD
Coronary Revascularization
before TAVI / Mitral
Interventions –
When and How?
Dariusz Dudek, MD, PhD
Hybrid Coronary
Revascularization for
Multivessel Disease – Should
it be a Common or Niche
Strategy? New Insights from
the HYBRID Trial
Michal Hawranek, MD, PhD
Hybrid Coronary
Revascularization for
Multivessel Disease – Would
Novel Antiplatelet and
Antithrombotic Compounds
Become a Mainstream
Strategy for the Future?
Krzysztof Milewski, MD
Switzerland
New Zealand
WE DNE SDAY,UniteMStates
ARCH 4
Australia
United Kingdom
7:00 – 10:00 AM
Canada
Japan
Denmark
MORNING SESSION
Greece
DUTCH SESSION
Italy
Slovenia
Czech Republic
Finland
Chairman:
Jacques J. Koolen, MD, PhD
Netherlands
What Innovations
in
Norway
Belgium
Coronary Artery Disease
will Change the Future?
Patrick W. Serruys,
MD, PhD
Brazuk
Bulgaria
Poland
Latvia
Edwards Sapien XT vs Edwards
Sapien 3
Spain
Guus Brueren, MD, PhD
Multivessel Disease Experience
from FAME 1, 2, and 3
Republic of
Croatia
Pim A.L. Tonino,
MD, PhDAustria
Macedonia
Single Center Experience
with Absorbable Stents:
Hungary
What is OurRussiaIndication? Romania
Jacques J. Koolen, MD, PhD
Paravalvular Leakage
after TAVR
Peter den Heijer, MD, PhD
Mitral Valve Clipping:
An Update
BJL Van den Branden, MD, PhD
DES or BMS in Patients on
Long-term Anticoagulants
Who Need PCI?
Willem Dewilde, MD
First European
Experience with Novel
Hypertension Treatment
Jan Van der Heyden, MD, PhD
Which Patients Benefit
from Bioreabsorbable
Scaffolds? The Five-year
Maasstad Hospital Experience
and Introduction to the
Multicenter COMPAREABSORB Trial
Pieter Smits, MD, PhD
The Heart of Women:
Playing Hard to Get?
Yolande Appelman, MD, PhD
MicroRNA’s Provide an
Optimal Target to Change
Cardiovascular Function
Pieter A. Doevendans, MD, PhD
Final Two-year Results of
the APPOSITION III Study
Evaluating the Use of the
STENTYS Self-apposing
Stent for the Treatment
of ST-Segment Elevation
Myocardial Infarction in the
Setting of Primary PCI
Karel T. Koch, MD, PhD
Predicting the EXCEL Results
from the SYNTAX Score II
Patrick W. Serruys, MD, PhD
3:30 – 6:00 PM
France
South Korea
Sweeden
AFTERNOON SESSION
Switzerland
JAPANESE SESSION
Germany
Japan
New Zealand
Australia
Chairmen: Osamu Katoh, MD,
Hideo Nishikawa, MD, PhD
Unite States
CTO-PCI: Past,UnitedPresent
Kingdom
and the Future
Osamu Katoh, MD
Denmark
Canada
CTO-PCI Registry in JapanSlovenia
Etsuo Tsuchikane, MD, PhD
Italy
Greece
Finland
CTO Guide PCIf
Takashi Akasaka, MD
Netherlands
Czech Republic
My Style of EVT
Norway
Belgium
Kazushi Urasawa, MD, PhD
Latvia
Recent Japanese Clinical Trials
Poland MD, PhDBrazuk
Hideo Nishikawa,
Bulgaria
Spain
Republic of
Macedonia
Hungary
Croatia
Russia
Austria
Romania
Netherlands
South Korea
Latvia
Switzerland
New Zealand
Norway
Bulgaria
Germany
Australia
BRITISH SESSION
Germany
Japan
7:00 – 10:00
AM
Switzerland
Poland
Sweeden
Brazuk
Lessons Learned or To Be
Learned from Randomized
Trials with BRS
Patrick W. Serruys, MD, PhD
New Zealand
Sweeden
South Korea
Japan
Canada
South Korea
MORNING SESSION
France
Target vs. Total
Revascularization in PCI
Charles
Ilsley,Slovenia
MD
Greece
Belgium
T H U R S D AY, M A R C H 5
France
Unite States
United Kingdom
Czech Republic
Finland
Sweeden
Spain
States
AMERICANUniteSESSION
IIIAustralia
Switzerland
New Zealand
A LITTLE BIT OF
SouthEP
Korea
France
Denmark
Unite States
Republic
of
Macedonia
UnitedAustralia
Kingdom
Croatia
The Future of TAVR
Acute Physiologic
Martin B. Leon, MD, FACC
Measurements during Primary Italy
Greece
Slovenia
Czech Republic
Finland
Stem Cells: State of the
Union
PCI to Predict Final Infarct Size
Hungary
Russia
Romania
Timothy D. Henry, MD, FACC
Andreas Baumbach, MD
Czech Republic
Netherlands
Finland Cents (sic)
What Makes
for
Fusion
Mapping
Norway
Belgium of
Treating Superficial Femoral
Physiology and Anatomy
(IVUS/Angiography) to Guide Latvia Disease in 2015: Balloons,
Belgium
Stents, or Norway
Atherectomy?
Clinical
Decision
Making
Brazuk
Poland
Mark W. Burket, MD, FACC
Justin Davies, MD, PhD
Sympathetic
Denervation:
Brazuk
Acute Cardiac Support:
Bulgaria
Poland
Spain
Are the Data Right and the
Current Role of LVAD
Doctor Wrong, or Vice Versa?
and VA ECMO
James R. Margolis,
MD, FACC
Spain
Andre R. Simon, MD, PhD
Denmark
United Kingdom
Canada
Italy
Greece
Slovenia
Netherlands
Finland
Czech Republic
Latvia
Bulgaria
Croatia
Austria
Human
Factors
in Acute
Cardiac Care
Mark Mason, MD
Norway
Poland
Belgium
Brazuk
PFO Closure: Are the Data
Right and the Doctor Wrong,
Vice Versa?
Republic or
of
Croatia
Austria
Macedonia
James R. Margolis, MD, FACC
Spain
Sweeden
AustriaCanada
Germany
Switzerland
New Zealand
Fighting Sudden Cardiac
Death Over the Last Three
Japan
Australia
Unite States
Decades: Progress
and
Challenges
Gerhard Hindricks, MD, PhD
Denmark
United Kingdom
Canada
Heart Failure and Cardiac
Implants: Resynchronization
and Novel Approaches
Greece
Italy
Slovenia
Christopher Piorkowski, MD
Catheter Ablation of
Finland
Ventricular Tachycardia
inCzech Republic
Patients with Organic Heart
Disease: Can We Replace
Latvia
Norway
Belgium
the ICD?
Philipp Sommer, MD
Netherlands
Brazuk
Bulgaria
Poland
Romania
CRRISiS in the
Cath Lab:
3:30 – 6:00 PM
Stable Angina: Are the Data
Simulated Emergency Training
AFTERNOON SESSION
the Doctor Wrong,
David Gareth Jones, BSc(Hons), Hungary Right and
Russia
Romania
Spain
or Vice Versa?
MBBS, MD(Res)
GERMAN SESSION
Sweeden Sweeden
France France
South Korea
South Korea
Jeffrey W. Moses, MD, FACC
The Future of Infarct
What is the Etiology of
Imaging? ...New Insights
New Zealand
New Zealand
Germany Germany
Switzerland
Switzerland
Arteriosclerosis: A DNA
Republic
of
Croatia
Austria
Chairmen:
from PET-MRI
Macedonia
Analysis
of
Receptive
Plaque
Nicolaus
Reifart,
MD,
FACC,
and
Steven K. White, BSc, MBChB
Richard R. Heuser, MD, FACC Japan Japan
Gerald S. Werner,
MD, PhD,
FACC
Australia Australia
Unite States
Unite States
Should We Lose Faith in
Left Atrial Appendage Closure
Concepts forRussiathe Treatment
Renal Denervation? Early
Hungary
Romania
Michael J. Rinaldi, MD, FACC
of SFA In-stent Restenosis
Findings Evaluating the
Denmark Denmark
Canada Canada
United Kingdom
United Kingdom
Hans Krankenberg, MD
Reduction in Blood Pressure
Precision Phenotyping and
in Pharmacological Controlled
Panomics for Biomarker and
Ascending Aorta: A New Field
Subjects Undergoing Distal
Drug Target Discovery: The
for Endovascular
Treatment?
Greece Greece
Italy
Italy
Slovenia Slovenia
and Branch Renal Artery
GLOBAL Study
Hans Krankenberg, MD
Denervation
Szilard Voros, MD, FACC
Cardiac MRI 20 Years Later
Justin Davies, MD, PhD
Czech Republic
Netherlands
Netherlands
Finland Finland
New Era in Lipid
Michael Pieper,
MD Czech Republic
Management?
25 Years Experience in CTO
Robert A. Vogel, MD, FACC
Latvia
Latvia
PCI: 5-Years
Inspired by
Norway Norway
Belgium Belgium
PCSK9 Inhibition:
EURO-CTO-CLUB
New Approach to Lipid
Markus Meyer-Gessner, MD
Management
Brazuk Brazuk
Bulgaria Bulgaria
Early and Poland
LatePoland
Management
David Kallend, MD
of Aortic Dissection
Dual or Triple Therapy
Christoph A. Nienaber, MD, PhD
Spain
Spain
for PCI Patients with
Monitored Euro-CTO Registry:
Atrial Fibrillation
A New Concept to Improve
Kurt Huber, MD, FACC
Quality Data
Republic of
Republic of
Croatia Croatia
Austria Austria
Nicolaus Reifart,
MD, FACC
MacedoniaMacedonia
Russia
Republic of
Macedonia
Hungary
Croatia
Russia
Austria
Romania
Hungary Hungary
Russia
Russia
Romania Romania
S C I E N T I F I C P R O GGermany
R A M 2 0 15
New Zealand
Switzerland
France
Japan
South Korea
Australia
Unite States
Germany
T H U R S DAY c on t inu ed
Denmark
Severe Calcification as a
Predictor of Outcome of
DCB Treatment in Peripheral
Arteries: Results of a Blinded
Core Lab Analysis and a
Possible Way to Overcome
this Issue with Atherectomy,
BTK Study Concept
Gunnar Tepe, MD
Italy
Netherlands
Latvia
The Impact of CTO on
Mortality in STEMI PCI:
Results of a Prospective
Multicentre Study of More
than 12,000 Patients
(FITT-STEMI)
Gerald S. Werner, MD, PhD, FACC
Bulgaria
Republic of
Macedonia
Clinical Important Drug
Interactions in Cardiovascular
Catheterizations and
Interventions
Hans-Friedrich Voehringer, MD
Hungary
Guiding the PCI in ACS:
From IVUS to OCT
Blaz Mrevjle, MD
Current Status of
Interventional Treatment of
Calcified Coronary Lesions
Hans Störger, MD
Sweeden
Switzerland
New Zealand
Unite States
Australia
F R I D AY, M A R C H 6
United Kingdom
Japan
Canada
7:00 – 10:00 AM
MORNING SESSION
Greece
DenmarkSlovenia
United Kingdom
CENTRAL/EASTERN
EUROPEAN SESSION III
Interventional Cardiology
beyond Coronary
Revascularization
Finland
Norway
Italy
Czech Republic
Belgium
Netherlands
Latvia
Brazuk
Spain
Bulgaria
Slovenia
Finland
Czech Republic
Norway
Poland
Beyond Revascularization
for Ischemic Heart Disease:
Significance of Mitral
Regurgitation and Mitral
Valve Repair
Witold Gerber, MD, PhD
Spain
Croatia
Russia
Austria
Republic of
Macedonia
Romania
Croatia
TAVI in Intermediate
Risk Patients
Adam Witkowski, MD, PhD
Hungary
Canada
Greece
Chairmen:
Dariusz Dudek, MD, PhD,
Andrzej Ochala, MD, and
Adam Witkowski, MD, PhD
Poland
The ROX Coupler:
Creation of a Fixed Central
Arterial-Venous Anastomosis
for the Treatment of Systemic
Arterial Hypertension
Adam Witkowski, MD, PhD
Russia
Feasibility and Clinical
Outcomes of TAVI in Difficult
Subsets: Bicuspid Aortic Valve,
Valve-in-valve Implantations
Radoslaw Parma, MD, PhD
Immediate and Long-term
Outcomes after TAVI in
Poland – POLTAVI Registry
New Generation TAVI
Dariusz Dudek, MD, PhD,
Adam Witkowski, MD, PhD
Incidence, Predictors and
Outcome of VARC2-defined
Acute Kidney Injury after TAVI
Andrzej Ochala, MD
Percutaneous Treatment
of Mitral Valve
Dariusz Dudek, MD, PhD
Transcatheter Closure
of Paravalvular Leaks
Grzegorz Smolka, MD, PhD
Revascularization Strategies
in STEMI in Very Old Patients
with Multivessel Disease
Lucian Zarma, MD
Is There a Place for New
Generation Percutaneous
Devices Designated for
the Treatment of Resistant
Hypertension?
Krzysztof Milewski, MD, PhD
Belgium
Safety and Performance
of Urinary Bladder Electrical
Stimulation in Acute
Decompensated Heart Failure
Andrejs Erglis, MD, PhD
Brazuk
Low/High Energy
Stimulation to Improve
Long-term Outcome after
Revascularization in Patients
with Ischemic Heart Failure
Zbigniew Kalarus, MD, PhD
Austria
Romania
Advanced Techniques
for Recanalization
of Peripheral Arteries
Stanislaw Bartus, MD, PhD
Advanced Strategy for
Revascularization of
High-risk Patients with
Multivessel, Diffuse Coronary
Artery Lesions
Pawel E. Buszman, MD, PhD, FACC
Discussion & Summary
REGISTRATION AND HOTEL INFORMATION
L O C AT I O N
H OT E L AC C O M M O DAT I O N S
The Westin Snowmass Resort
Snowmass Village, Colorado
A block of rooms has been reserved at the
Westin Snowmass Resort and in limited quantities
at the adjacent Wildwood Snowmass. Please
contact the hotel directly for room reservations
at 800-525-9402 or 970-923-3520. In order to
receive the special rates below, you must mention
the Interventional Cardiology 2015 symposium.
Reservations must be received by the Westin
Snowmass Resort no later than end of business
day, February 6, 2015.
R E G I S T R AT I O N
Physician/Industry
$1,050 through January 16, 2015
$1,250 after January 16, 2015
Resident/Fellow/Nurse
$550 through January 16, 2015
$750 after January 16, 2015
Please make checks payable to Promedica
International CME in US dollars drawn on a US
bank. Visa, MasterCard, American Express and
Discover cards are also accepted.
Please register online at www.promedicacme.com.
If you prefer, you may complete the form below
and mail or fax it to:
Promedica International CME
300 Carlsbad Village Drive, Suite 108A-326
Carlsbad, CA 92008
Tel: (760) 720-2263
Fax: (760) 720-6263
Email: [email protected]
Special rates for Interventional Cardiology 2015
participants are below. Please note that a resort
fee and applicable taxes will be added to the
nightly rates.
$345 Westin Alpine Room (king)
$375 Westin Deluxe Pinnacle Room
(2 queens or king)
$395 Westin Premium Pinnacle Room
(2 queens or king) aka “Slopeview”
$199 Wildwood Room (2 doubles or king)
All reservations must be guaranteed and
accompanied by a deposit of 25% of the total
room night revenue at the time of booking. The
balance is due 30 days prior to arrival.
REFUNDS
All cancellations must be submitted in writing
and refunds will be subject to a $100 administration charge. Cancellations cannot be accepted over
the telephone. Refunds will not be available after
January 16, 2015.
CONFERENCE PRODUCED BY
PROMEDICA INTERNATIONAL CME
Look for continuous updates on our website
at www.promedicacme.com
Interventional Cardiology 2015: 30TH Annual International Symposium
March 1–6, 2015
Physician/Industry
Resident/Fellow/Nurse
 $1,050 Through January 16, 2015
 $550 Through January 16, 2015
 $1,250 After January 16, 2015
 $750 After January 16, 2015
PAYM EN T All fees in US dollars drawn on US banks:  Check Enclosed  Visa/MasterCard  American Express
REGISTR ATI O N CREDIT CARD NUMBER
EXPIRATION DATE
 Discover
SIGNATURE
FIRST/LAST NAME
 MD
 RN
HOSPITAL/COMPANY
MAILING ADDRESS
CITY/STATE/ZIP/COUNTRY
TELEPHONEFAX
EMAIL ADDRESS
Card
SPECIALTY
SEND TO
Laurel Steigerwald, Promedica International CME
300 Carlsbad Village Drive, Suite 108A-326, Carlsbad, CA 92008 Tel: (760) 720-2263, Fax: (760) 720-6263
e-mail: [email protected]
 CCP
Interesting and inspiring talks and very engaged discussions
with top shots in a perfect environment.
This meeting is one of the best in the world for international
networking and invasive cardiology!
Excellent content and a most thorough presentation and
discussion of the important issues in interventional medicine.
The faculty was exceptional…the enthusiasm contagious!
Great international view of different approaches
to disease management.
One of the best programs available in interventional cardiology!
HERE’S WHAT THEY’RE SAYING
Promedica International CME
300 Carlsbad Village Drive, Suite 108A-326
Carlsbad, CA 92008
Presort Standard
U.S. Postage
PAID
Permit 1948
San Diego CA

Similar documents